ReviewJournal of anesthesia2026
Anesthesia and mitochondria: balancing toxicity and protection through emerging therapeutic strategies.
Review in Journal of anesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Cognitive and Functional Outcomes of Anesthesia and Surgery in Patients with Dementia.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anesthesia is a cornerstone of modern surgical practice, enabling interventions by deliberately modulating nociception and consciousness-from localized analgesia and mild sedation to deep unconsciousness. Yet the molecular and cellular mechanisms that produce these reversible states remain only partly defined, constraining our ability to predict interpatient variability, prevent mitochondrial- and neurotoxicity-related adverse effects, and optimize agent selection, dosing, and timing across perioperative care. Beyond their intended effects, anesthetics and their adjuvants impose substantial physiological stress on the brain, metabolism, and immune system, with particularly pronounced risks in vulnerable populations such as pediatric and elderly patients with developing and otherwise fragile neural networks. Recent studies have highlighted mitochondria, the cell's energy processing unit and key regulator of homeostasis, as especially susceptible to anesthetic exposure. Evidence indicates that agents used in the perioperative period may disrupt mitochondrial function by altering oxidative phosphorylation, increasing reactive oxygen species (ROS) production, and impairing mitochondrial dynamics. Such disruptions can contribute to neurotoxicity, metabolic dysregulation, and immune suppression, potentially affecting postoperative recovery and long-term cognitive outcomes. This review critically examines emerging data on the interplay between anesthesia agents and mitochondrial function. We discuss the implications of mitochondrial dysfunction for neural health and postoperative recovery, and we highlight current and prospective strategies to possibly refine anesthesia drug protocols through targeted mitochondrial therapeutics. Ultimately, a deeper understanding of these mitochondrial interactions is imperative for developing safer, more effective anesthesia practices, especially for pediatric and other high-risk patient populations.
Indexed as
Identifiers
41045340What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.